# OnCo record stelexis-biosciences (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/stelexis-biosciences/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "stelexis-biosciences" ;
  schema:name "Stelexis BioSciences"@en ;
  schema:alternateName "Stelexis Therapeutics"@en ;
  schema:description "Stelexis BioSciences develops medicines for blood cancers that aim at the earliest faulty stem cells behind them. Its lead is a tablet that blocks an enzyme called PI3K-gamma, tested in acute myeloid leukaemia and higher-risk myelodysplastic syndromes."@en ;
  schema:url <https://onco.cc/companies/stelexis-biosciences/>, <https://stelexis.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://stelexis.com/>, <https://stelexis.com/pipeline/>, <https://www.prnewswire.com/news-releases/stelexis-therapeutics-closes-43-million-series-a-to-expand-novel-platform-focused-on-cancer-interception-300773175.html>, <https://clinicaltrials.gov/study/NCT06533761> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds-higher-risk/>, <https://onco.cc/cancers/cmml/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:targets <https://onco.cc/targets/pik3cg/> .